CorMedix Inc. (NYSEMKT:CRMD) has been given a $3.00 price target by equities research analysts at HC Wainwright in a report issued on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock.

Several other brokerages have also recently weighed in on CRMD. FBR & Co reaffirmed a “buy” rating on shares of CorMedix in a research report on Monday, April 24th. Zacks Investment Research raised shares of CorMedix from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research report on Tuesday, April 25th. Finally, Rodman & Renshaw lowered their price target on shares of CorMedix from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, May 5th.

Shares of CorMedix (CRMD) opened at 0.3647 on Thursday. The stock’s market capitalization is $14.82 million. CorMedix has a 12-month low of $0.34 and a 12-month high of $3.26. The stock’s 50 day moving average is $0.40 and its 200-day moving average is $1.08.

CorMedix (NYSEMKT:CRMD) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.06. CorMedix had a negative net margin of 19,203.39% and a negative return on equity of 211.19%. On average, analysts expect that CorMedix will post ($0.60) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “CorMedix Inc. (NYSEMKT:CRMD) PT Set at $3.00 by HC Wainwright” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/cormedix-inc-nysemktcrmd-pt-set-at-3-00-by-hc-wainwright/1468169.html.

In other news, CEO Khoso Baluch acquired 75,000 shares of CorMedix stock in a transaction that occurred on Wednesday, May 17th. The stock was purchased at an average price of $0.48 per share, for a total transaction of $36,000.00. Following the purchase, the chief executive officer now directly owns 85,000 shares in the company, valued at approximately $40,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have purchased 203,781 shares of company stock valued at $98,362.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Receive News & Ratings for CorMedix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.